Overview

A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for Instillation (VAX014) in patients with low-grade Non-Muscle Invasive Bladder Cancer (NMIBC). VAX014 is a targeted oncolytic agent designed to kill tumor cells following instillation into the urinary bladder.
Phase:
Phase 1
Details
Lead Sponsor:
Vaxiion Therapeutics